人促肾上腺皮质激素释放激素试验:垂体与肾上腺疾病10年真实世界经验
该横断面研究纳入2010至2019年一家转诊大学医院中心的200例患者,评估人促肾上腺皮质激素释放激素试验(hCRHtest)的诊断准确性。hCRHtest主要用于ACTH依赖性库欣综合征或肾上腺病变的鉴别诊断(P = .048);ACTH和皮质醇的峰值升高百分比能以敏感性和特异性均大于80%区分库欣病与异位ACTH分泌。在基础ACTH低或不确定的患者中,ACTH峰值反应缺失或降低可区分肾上腺性与ACTH依赖性形式。
要点
- hCRHtest主要用于ACTH依赖性库欣综合征或肾上腺病变的鉴别诊断(P = .048)。
- ACTH和皮质醇的峰值升高百分比区分库欣病与异位ACTH分泌的敏感性和特异性均大于80%。
- 基础ACTH低(< 10 pg/mL)或不确定(10-20 pg/mL)时,ACTH峰值反应缺失或降低可区分肾上腺性与ACTH依赖性形式。
核心结论
- hCRHtest是ACTH依赖性库欣综合征鉴别诊断的主要手段。
- 在双侧肾上腺肿块患者中,hCRHtest也有助于提示库欣病的诊断。
- 在基础ACTH低的患者中,hCRHtest也有助于提示库欣病的诊断。
研究设计与样本
- 横断面研究,纳入2010至2019年一家转诊大学医院中心的200例患者:库欣病86例、异位ACTH分泌15例、肾上腺性库欣综合征18例、轻度肾上腺自主皮质醇分泌25例、假性库欣综合征31例、疑似肾上腺功能不全25例。
- 静脉推注100 μg人促肾上腺皮质激素释放激素后测定ACTH和皮质醇水平,收集峰值(peakACTH和peakcortisol),并计算升高百分比(∆%ACTH和∆%cortisol)。
主要发现
- hCRHtest主要用于ACTH依赖性库欣综合征或肾上腺病变的鉴别诊断(P = .048)。
- 库欣病患者的peakACTH和peakcortisol较高,∆%ACTH和∆%cortisol区分库欣病与异位ACTH分泌的敏感性和特异性均大于80%。
- 在基础ACTH低(< 10 pg/mL)或不确定(10-20 pg/mL)的患者中,ACTH峰值反应缺失或降低可区分肾上腺性与ACTH依赖性形式。
- 假性库欣综合征患者hCRHtest后的peakACTH和peakcortisol低于库欣病患者,但∆%ACTH和∆%cortisol相似。
- hCRHtest在肾上腺功能不全患者中的作用有限。
关键数值与推荐
- ∆%ACTH和∆%cortisol区分库欣病与异位ACTH分泌的敏感性和特异性均大于80%。
- 基础ACTH低定义为< 10 pg/mL,不确定定义为10-20 pg/mL。
- hCRHtest使用100 μg人促肾上腺皮质激素释放激素静脉推注。
临床怎么用
- hCRHtest是ACTH依赖性库欣综合征鉴别诊断的主要手段。
- 在双侧肾上腺肿块患者中,hCRHtest有助于提示库欣病的诊断。
- 在基础ACTH低的患者中,hCRHtest有助于提示库欣病的诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The human corticotropin-releasing hormone (CRH) test (hCRHtest) is used to differentiate Cushing disease (CD) from ectopic adrenocorticotropin (ACTH) secretion (EAS), to assess autonomous cortisol secretion by the adrenal glands, and to characterize pseudo-Cushing syndrome (CS) or adrenal insufficiency (AI). MAIN OUTCOME MEASURE: The main outcome measure of this study was to assess the diagnostic accuracy of the hCRHtest. METHODS: We measured ACTH and cortisol levels; collected the peak values (peakACTH and peakcortisol), and calculated the percentage increases (∆%ACTH and ∆%cortisol) after an intravenous bolus of 100 μg hCRH. DESIGN AND SETTING: This cross-sectional study of hCRH tests from 2010 to 2019 took place in a referral university hospital center. PATIENTS: We enrolled 200 patients: 86 CD, 15 EAS, 18 adrenal CS, 25 mild adrenal autonomous cortisol secretion, 31 pseudo-CS, and 25 suspected AI. RESULTS: The hCRHtest was performed mainly for the differential diagnosis of ACTH-dependent CS or adrenal lesions (P = .048). PeakACTH and peakcortisol were higher in CD, and ∆%ACTH and ∆%cortisol were able to differentiate CD from EAS with a sensitivity and specificity greater than 80%. In patients with low (< 10 pg/mL) or indeterminate (10-20 pg/mL) basalACTH levels, an absent or reduced peakACTH response was able to differentiate adrenal from ACTH-dependent forms. PeakACTH and peakcortisol after hCRHtest were lower in pseudo-CS than in CD, but ∆%ACTH and ∆%cortisol were similar. The role of hCRHtest in patients with AI was limited. CONCLUSIONS: The hCRHtest test is the mainstay of the differential diagnosis of ACTH-dependent CS. It is also useful for pointing to a diagnosis of CD in the event of bilateral adrenal masses, and in patients with low basalACTH.
引用
- Ceccato F, Tizianel I, Vedolin CK, et al. Human Corticotropin-Releasing Hormone Tests: 10 Years of Real-Life Experience in Pituitary and Adrenal Disease. J Clin Endocrinol Metab. 2020. PMID: 32818260. doi:10.1210/clinem/dgaa564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。